Artiva Biotherapeutics, Inc. ARTV Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Finance Lease, Right-of-Use Asset, after Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAsset.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s finance lease, right-of-use asset, after accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s finance lease, right-of-use asset, after accumulated amortization?
- Artiva Biotherapeutics, Inc. (ARTV) reported finance lease, right-of-use asset, after accumulated amortization of $196K in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s finance lease, right-of-use asset, after accumulated amortization changed year-over-year?
- Artiva Biotherapeutics, Inc.'s finance lease, right-of-use asset, after accumulated amortization decreased by 20.3% year-over-year, from $246K to $196K.